AU2010336441B2 - Highly permeating terbinafine formulation for treating onychomycosis - Google Patents

Highly permeating terbinafine formulation for treating onychomycosis Download PDF

Info

Publication number
AU2010336441B2
AU2010336441B2 AU2010336441A AU2010336441A AU2010336441B2 AU 2010336441 B2 AU2010336441 B2 AU 2010336441B2 AU 2010336441 A AU2010336441 A AU 2010336441A AU 2010336441 A AU2010336441 A AU 2010336441A AU 2010336441 B2 AU2010336441 B2 AU 2010336441B2
Authority
AU
Australia
Prior art keywords
formulation
formulations
terbinafine
permeation
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010336441A
Other languages
English (en)
Other versions
AU2010336441A1 (en
Inventor
Nadir Buyuktimkin
Servet Buyuktimkin
Dominic King-Smith
Edward Kisak
John M. Newsam
Jagat Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvo Research Inc
Original Assignee
Nuvo Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvo Research Inc filed Critical Nuvo Research Inc
Publication of AU2010336441A1 publication Critical patent/AU2010336441A1/en
Application granted granted Critical
Publication of AU2010336441B2 publication Critical patent/AU2010336441B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2010336441A 2009-12-23 2010-12-22 Highly permeating terbinafine formulation for treating onychomycosis Ceased AU2010336441B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28996209P 2009-12-23 2009-12-23
US28996709P 2009-12-23 2009-12-23
US61/289,967 2009-12-23
US61/289,962 2009-12-23
PCT/US2010/061940 WO2011079234A2 (en) 2009-12-23 2010-12-22 Highly permeating terbinafine formulation

Publications (2)

Publication Number Publication Date
AU2010336441A1 AU2010336441A1 (en) 2012-08-02
AU2010336441B2 true AU2010336441B2 (en) 2015-02-05

Family

ID=43770418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010336441A Ceased AU2010336441B2 (en) 2009-12-23 2010-12-22 Highly permeating terbinafine formulation for treating onychomycosis

Country Status (7)

Country Link
US (1) US9084754B2 (enExample)
EP (1) EP2544659A2 (enExample)
JP (1) JP5829217B2 (enExample)
CN (1) CN102770123A (enExample)
AU (1) AU2010336441B2 (enExample)
CA (1) CA2785643A1 (enExample)
WO (1) WO2011079234A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012215383B2 (en) 2011-02-11 2016-06-09 Moberg Pharma Ab Novel antifungal composition
CN104105472A (zh) * 2011-12-20 2014-10-15 维奥姆生物科学有限公司 用于治疗真菌感染的局部油组合物
EP2664327A1 (en) 2012-05-14 2013-11-20 Almirall S.A. Topical pharmaceutical compositions comprising terbinafide and urea
NL2009669C2 (en) * 2012-10-19 2014-04-23 Dutch Renewable Energy B V Enhanced nail penetrating composition.
AU2013361106B2 (en) 2012-12-21 2017-06-01 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
US8697753B1 (en) 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
EP2952208A1 (en) * 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalcoholic system for nail treatment
CN118453831A (zh) 2014-10-21 2024-08-09 戴夫生物技术私人有限公司 一种治疗方法
KR101690765B1 (ko) * 2015-04-17 2016-12-28 동아제약 주식회사 항진균성 활성물질을 포함하는 경피 제제
GB201511799D0 (en) * 2015-07-06 2015-08-19 Blueberry Therapeutics Ltd Composition and methods of treatment
EP3337471A4 (en) * 2015-08-17 2019-04-10 Ohio State Innovation Foundation METHOD AND COMPOSITIONS FOR IMPROVED TRANSITIONAL DELIVERY OF AR-12
US10272054B2 (en) * 2015-10-07 2019-04-30 Exodos Life Sciences Lp Topical antifungal compositions
GB201605127D0 (en) * 2016-03-25 2016-05-11 Blueberry Therapeutics Ltd Composition and methods of treatment
WO2017216722A2 (en) * 2016-06-13 2017-12-21 Vyome Biosciences Pvt. Ltd. Synergistic antifungal compositions and methods thereof
KR20190037229A (ko) * 2016-06-13 2019-04-05 바이옴 테라퓨틱스 리미티드 상승효과적 항진균 조성물 및 그의 방법
IL287622B (en) 2016-11-28 2022-07-01 Cellix Bio Private Ltd Preparations and methods for treating fungal infections
WO2019214838A1 (en) * 2018-05-09 2019-11-14 Eviderm Institute Ab Use of an alcohol-containing composition for improving the skin barrier function
WO2019234546A1 (en) * 2018-06-04 2019-12-12 Zenvision Pharma Llp Antifungal cuticle oil composition
EP3603650A1 (fr) 2018-08-01 2020-02-05 Edix O Sarl Compositions injectables et a duree d'action prolongee pour leur utilisation dans le traitement de maladies de l'ongle et/ou pour accelerer la croissance de l'ongle
CN112888443A (zh) 2018-08-01 2021-06-01 爱迪克斯-欧有限公司 用于其在治疗指或趾甲疾病中的使用和/或用于加速指或趾甲生长的具有延长的作用持续时间的可注射组合物
EP3941985A4 (en) 2019-03-19 2022-11-02 Dow Global Technologies LLC AQUEOUS DISPERSION WITH MULTISTAGE POLYMER PARTICLES
CN113208937A (zh) * 2020-01-21 2021-08-06 中国医学科学院北京协和医院 一种角质软化组合物及其制备方法和应用及治疗灰指甲的外用复方及其制备方法和应用
JP7664026B2 (ja) * 2020-08-06 2025-04-17 沢井製薬株式会社 エフィナコナゾール含有爪外用液
JP2022117408A (ja) * 2021-01-29 2022-08-10 花王株式会社 外用剤組成物
CN113234028B (zh) * 2021-04-29 2022-08-26 上海大学 一种5-氟尿嘧啶与肌氨酸的共晶体及其制备方法与用途
CN113786382B (zh) * 2021-11-04 2024-05-28 浙江得恩德制药股份有限公司 一种盐酸特比萘芬凝胶及制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042059A1 (en) * 2004-10-08 2006-04-20 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
WO2011014850A2 (en) * 2009-07-31 2011-02-03 Nuvo Research Inc. Topical eutectic-based formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7713618L (sv) 1977-12-01 1979-06-02 Astra Laekemedel Ab Lokalanestetisk blandning
IT1180295B (it) 1984-10-08 1987-09-23 Durst Phototechnik Srl Ingranditore o riproduttore fotografico a colori
FR2673537B1 (fr) 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
CN1255850A (zh) 1997-05-14 2000-06-07 盖伦(化学制品)有限公司 局部用组合物
DE69918087D1 (de) * 1998-04-17 2004-07-22 Bertek Pharm Inc Topische formulierungen zur behandlung von nagel pilzerkrankungen
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
DE10035991A1 (de) * 2000-07-24 2002-02-14 Polichem Sa Nagellackzusammensetzung
DE60223694T2 (de) 2001-09-04 2008-10-30 Trommsdorff Gmbh & Co. Kg Arzneimittel Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
US20030091666A1 (en) * 2001-11-14 2003-05-15 Howard Murad Methods and compositions for treating dermatological disorders with Morinda citrifolia
US7138394B2 (en) 2002-09-27 2006-11-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
HRP20050918A2 (en) * 2003-03-21 2006-12-31 Nexmed Holdings Antifungal nail coat and method of use
CA2536482C (en) 2003-08-25 2012-07-24 Foamix Ltd. Penetrating pharmaceutical foam
US20060078599A1 (en) 2004-10-12 2006-04-13 Mathew Ebmeier Pharmaceutical composition applicable to body tissue
CA2500907A1 (en) 2005-03-15 2006-09-15 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
EP1858556A1 (en) 2005-03-16 2007-11-28 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
GB0511499D0 (en) * 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
US20070224261A1 (en) 2006-03-22 2007-09-27 Peter Draper Eutectic liquid drug formulation
EP2457560A1 (en) 2006-06-14 2012-05-30 Dr Reddy's Laboratories Limited Topical compositions
WO2008121709A1 (en) * 2007-03-30 2008-10-09 Transport Pharmaceuticals, Inc. Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug
CA2731455A1 (en) 2008-07-23 2010-01-28 Gregor Cevc Methods of administering topical antifungal formulations for the treatment of fungal infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042059A1 (en) * 2004-10-08 2006-04-20 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
WO2011014850A2 (en) * 2009-07-31 2011-02-03 Nuvo Research Inc. Topical eutectic-based formulations

Also Published As

Publication number Publication date
AU2010336441A1 (en) 2012-08-02
EP2544659A2 (en) 2013-01-16
US20120309843A1 (en) 2012-12-06
CN102770123A (zh) 2012-11-07
US9084754B2 (en) 2015-07-21
JP2013515742A (ja) 2013-05-09
JP5829217B2 (ja) 2015-12-09
CA2785643A1 (en) 2011-06-30
WO2011079234A3 (en) 2011-08-18
WO2011079234A2 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
US9084754B2 (en) Highly permeating terbinafine formulation
WO2011014850A2 (en) Topical eutectic-based formulations
US20150342871A1 (en) Highly permeating terbinafine formulation
CN102711835B (zh) 局部布洛芬制剂
US5807568A (en) Enhanced delivery of topical compositions containing flurbiprofen
US20160058723A1 (en) Composition for external use preparation with improved transdermal permeability
US20140004176A1 (en) Delivery of treatments transdermally for fungal infections and other indications
US9289495B2 (en) Systems and methods for treatment of allergies and other indications
JP2016033168A (ja) Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法
EP2498819A2 (en) Topical etoricoxib formulation comprsing an eutectic mixture of permeation enhancers
US20200383910A1 (en) Topical formulation
WO2021222453A1 (en) Fast-acting topical anesthetic formulations
EP4658241A1 (en) Compositions for topical administration
JP2016188261A (ja) ヒストンデアセチラーゼ阻害薬のための医薬製剤
ES2402921T3 (es) Composiciones químicamente estables de 4-hidroxi-tamoxifeno y sus aplicaciones terapéuticas
EP2575813A1 (en) Topical etoricoxib formulation
US20160081915A1 (en) Transdermal formulations of fluticasone
EP2482850A2 (en) Topical formulations
ES2444398T3 (es) Composiciones farmacéuticas tópicas de ketoprofeno y metilsulfonilmetano
WO2007086582A1 (ja) ２２－オキサ－１α,２５－ジヒドロキシビタミンＤ3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法
JP2024507011A (ja) エマルション組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用
CA3177346A1 (en) Fast-acting topical anesthetic formulations
US20200368353A1 (en) Systems and methods for topical creams for warming
Stinchcomb In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired